Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Tryptamine Therapeutics ( (AU:TYP) ) has provided an announcement.
Tryptamine Therapeutics Limited has announced a change in the director’s interest in securities. Gage Jull, a director of the company, has experienced a lapse in director options due to the vesting conditions not being met as of December 31, 2024. This change does not affect the current number of ordinary fully paid shares held by the director but results in the reduction of 1,000,000 previously held director options.
More about Tryptamine Therapeutics
YTD Price Performance: -7.50%
Average Trading Volume: 4,025,654
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$47.23M
For an in-depth examination of TYP stock, go to TipRanks’ Stock Analysis page.
